Activating mutations in NOTCH1 are found in over 50% of human T-cell lymphoblastic leukemias (T-ALLs). Here, we report the analysis for activating NOTCH1 mutations in a large number of acute myeloid leukemia (AML) primary samples and cell lines. We found activating mutations in NOTCH1 in a single M0 primary AML sample, in three (ML1, ML2 and CTV-1) out of 23 AML cell lines and in the diagnostic (myeloid) and relapsed (T-lymphoid) clones in a patient with lineage switch leukemia. Importantly, the ML1 and ML2 AML cell lines are derived from an AML relapse in a patient initially diagnosed with T-ALL.
Introduction
Aberrant activation of the NOTCH1 signaling pathway induces transformation of T-cell progenitors and is broadly involved in the pathogenesis of human T-cell lymphoblastic leukemia (T-ALL). Activating mutations in NOTCH1 that disrupt the heterodimerization (HD) and PEST domains of the receptor are present in over 50% of human T-ALL cases. 1 Importantly, small molecule g-secretase inhibitors, which can effectively block activation of NOTCH1 signaling in vitro and in vivo, 1-3 may have antileukemic effects and are being tested to assess their efficacy in the treatment of T-ALL.
In contrast with the prevalent role of NOTCH1 activation in T-cell development, the role of NOTCH1 signaling in the myeloid development is not well-established. Activation of NOTCH1 signaling by enforced expression of a constitutively activated Notch1 gene or by treatment with NOTCH ligands induces the inhibition of granulocytic differentiation and the preservation of an immature phenotype both in myeloid leukemia cell lines (32D and HL60) and in primary myeloid progenitor cells, suggesting a possible role for NOTCH pathway activation in acute myeloid leukemia (AML). [4] [5] [6] [7] [8] [9] [10] [11] However, these results are controversial, as NOTCH1 signaling has also been shown to promote the maturation of myeloid progenitor cells. 12 Here, we report that although infrequent, activating NOTCH1 mutations can occur in human AML and in leukemia cases with lineage infidelity, suggesting that these mutations may occur in a leukemic stem cell that precedes both myeloid and T-lineage commitment.
Methods

Clinical samples
Clinical samples were obtained with informed consent under the supervision of the Institutional Review Board of the participating institutions (Dana-Farber Cancer Institute, Ohio State University, University of Tsukuba and University of Crete).
Western blot analysis of NOTCH1 in AML cell lines
Western blot analysis was performed using antibodies against the transactivation domain (TAD) of NOTCH1 and activated NOTCH1 Val 1774 antibody (Cell Signaling Technologies, Danvers, MA, USA).
NOTCH1 mutation analysis
Mutation screening was performed by direct sequencing after polymerase chain reaction (PCR) amplification of NOTCH1 exons 26, 27 and 34. Primer sequences and detailed PCR procedures are available upon request.
Luciferase reporter assays
A luciferase reporter assay was performed as previously described by Weng et al. 1 Briefly, U2OS cells were transfected with a NOTCH-CSL reporter vector and expression vectors (pCDNA3) containing NOTCH1 wild-type or the F1593L 1594 ins S NOTCH1 allele, or empty vector used as control. A Renilla luciferase expression vector was used to correct for differences in transfection efficiency.
Results and discussion
AML cell lines have high levels of NOTCH1 expression
As a first step to determine the potential role of NOTCH1 in AML, we analyzed the expression of the NOTCH1 receptor by Western blotting in a panel of 24 AML cell lines using a TADspecific NOTCH1 antibody (NOTCH1-TAD). Variable levels of NOTCH1 expression were detected with the highest levels of expression in K562 cells (Figure 1a ). This analysis showed that, in addition to the unprocessed NOTCH1 and the transmembrane portion of the mature receptor (NOTCH1-TM), four cell lines (HL60, ML2, OCI/AML3 and SKM1) have lower molecular weight proteins recognized by the NOTCH1-TAD antibody, which are similar to those found in T-ALL cells that harbor activating NOTCH1 mutations (Figure 1a and b) . 1 
Activating mutations in NOTCH1 in AML
To test whether the shorter forms of NOTCH1 detected by Western blot are due to activating mutations in NOTCH1, we sequenced the HD and PEST domains of NOTCH1 in an extended panel of cell lines (ML-1, KU-812, CMK-1, CTV-1, JURL-MK1, KCL-22, NB-4, THP-1, MEG-01, HL-60, Kasumi-1, U-937, ML-2, EM-2, LAMA-84, KG-1, SKM-1, MV-4;11, HEL, ML1, ML2, K-562 and MOLM-13). This analysis demonstrated the presence of truncating mutations in the PEST domain of NOTCH1 in three cell lines. CTV-1 cells, a minimally differentiated myeloid line derived from an AML M5 patient at relapse, 13, 14 showed a point mutation (7580C/A), generating a premature stop codon at position 2527 in NOTCH1 (Figure 1c) . In addition, two myelo-monocytic (AML M4) sister cell lines, ML1 and ML2, harbor a frameshift mutation as a result of a dinucleotide deletion at positions 7550-7551 (Figure 1d ). The presence of this mutation in two lines derived from the same patient strongly suggests that this mutation was present in the original patient sample and did not occur during the process of culture in vitro. PEST mutations identified in CTV-1, ML1 and ML2 cells are prototypical activating NOTCH1 mutations similar to those previously reported in T-ALL. 
Role of lineage infidelity
The ML1 and ML2 myeloid cell lines were derived from an M5 AML relapse in a patient initially diagnosed with T-ALL. 15, 16 Lineage switch at relapse in this patient was associated with cytogenetic progression, with acquisition of a t(6;11), resulting in expression of the MLL-AF6 fusion oncogene. 17 Based on these observations, we hypothesized that the NOTCH1 mutation found in ML1 and ML2 cells was originally present in preleukemic cells in the stem cell compartment or in a preleukemic early progenitor cell with T-lymphoid/myeloid potential.
To further assess the significance of this finding, we analyzed paired diagnostic and relapsed samples from two patients with lineage switch leukemias. The first of these patients presented with AML at initial diagnosis and developed lineage switch to T-ALL at relapse. 18 Both the diagnostic AML sample and T-ALL cells at relapse from this case harbored a truncating mutation (TGGT insertion at position 7423) in the PEST domain of NOTCH1, supporting the origin of NOTCH1 mutations in an earlier common precursor or 'leukemic stem cell' in these leukemias (Figure 1f) . In contrast, sequence analysis of samples from a second patient with lineage switch leukemia presenting with T-ALL and relapsing as AML 19 failed to show any mutations in the HD and PEST domains of NOTCH1.
The analysis of NOTCH1 mutations in AML cell lines showed no correlation between the presence of activating mutations in NOTCH1 and the presence of smaller size bands in the Western blot detected with the anti-NOTCH1 TAD antibody (see Figure  1a and b). To test whether the presence of these smaller NOTCH1 isoforms was associated with increased levels of NOTCH1 signaling, we performed a Western blot analysis with an antibody against activated NOTCH1. This analysis confirmed the presence of activated NOTCH1 in CTV-1 cells, but not in ML2 cells or any of the other cell lines with small NOTCH1 isoforms (Figure 1b) . The absence of detectable activated NOTCH1 protein in ML2 cells is intriguing and may reflect a downregulation of specific factors present in T cells and undifferentiated progenitors that are required to trigger NOTCH1 signaling in cells harboring PEST mutant alleles. 1 Overall, these results show that activating mutations in NOTCH1 are mostly restricted to T-ALL although can be found in rare cases of AML, particularly in the context of lineage switch leukemias. The presence of NOTCH1 mutations in AML and T-ALL blasts suggests that such mutations may originate from a leukemic stem cell in AML cases with lineage infidelity. Figure 2 The AML NOTCH1 mutation F1593L 1594 ins S encodes a constitutive active form of the NOTCH1 receptor. Transfection of U2OS cells with a expression vector (pCDNA3) containing the HD NOTCH1 mutation F1593L 1594 ins S in U2OS cells showed marked increased in a NOTCH-responsive luciferase reporter gene activity compared with empty vector and wild-type NOTCH1 controls. An internal Renilla luciferase internal control plasmid was included to control for differences in transfection efficiency.
